ValuEngine Downgrades Evoke Pharma (NASDAQ:EVOK) to Sell

Evoke Pharma (NASDAQ:EVOK) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday, ValuEngine reports.

EVOK has been the subject of several other research reports. Zacks Investment Research cut GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. HC Wainwright cut Hydrogenics from a “buy” rating to a “neutral” rating in a research note on Friday, June 28th.

Shares of Evoke Pharma stock traded up $0.01 during trading hours on Tuesday, hitting $0.88. 49,667 shares of the company were exchanged, compared to its average volume of 620,226. Evoke Pharma has a 1 year low of $0.50 and a 1 year high of $3.40. The firm has a 50-day simple moving average of $0.64. The firm has a market capitalization of $21.02 million, a PE ratio of -1.91 and a beta of 1.62.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.04). On average, research analysts forecast that Evoke Pharma will post -0.41 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in Evoke Pharma in the first quarter worth $139,000. BlackRock Inc. raised its position in Evoke Pharma by 5.5% in the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock worth $207,000 after acquiring an additional 4,392 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Evoke Pharma in the first quarter worth $118,000. Institutional investors and hedge funds own 7.40% of the company’s stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Read More: Diluted Earnings Per Share

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit